Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT01506609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.
Study identification
- NCT ID
- NCT01506609
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 294 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2012 (Actual)
- Primary completion
- Dec 13, 2018 (Actual)
- Completion
- Sep 2, 2020 (Actual)
- Last update posted
- Oct 25, 2021
2012 – 2020
United States locations
- U.S. sites
- 34
- U.S. states
- 17
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 62994 | Birmingham | Alabama | 35233 | — |
| Banner MD Anderson Cancer Ctr /ID# 118695 | Gilbert | Arizona | 85234 | — |
| University of Arkansas for Medical Sciences /ID# 60750 | Little Rock | Arkansas | 72205 | — |
| Moore UC San Diego Cancer Center /ID# 60754 | La Jolla | California | 92093 | — |
| The Angeles Clinic and Researc /ID# 60743 | Los Angeles | California | 90025 | — |
| Stanford University School of Med /ID# 65488 | Stanford | California | 94305-2200 | — |
| Cedars-Sinai Medical Center - West Hollywood /ID# 60760 | West Hollywood | California | 90048 | — |
| Univ of Colorado Cancer Center /ID# 60751 | Aurora | Colorado | 80045 | — |
| Lynn Cancer Institute, Boca /ID# 60749 | Boca Raton | Florida | 33486 | — |
| Holy Cross Hospital /ID# 62995 | Fort Lauderdale | Florida | 33308 | — |
| Moffitt Cancer Center /ID# 60746 | Tampa | Florida | 33612-9416 | — |
| Florida Cancer Specialists - East /ID# 60762 | West Palm Beach | Florida | 33401 | — |
| University of Illinois - Chicago /ID# 106175 | Chicago | Illinois | 60607 | — |
| Northwestern University Feinberg School of Medicine /ID# 60755 | Chicago | Illinois | 60611-2927 | — |
| Rush University Medical Center /ID# 65489 | Chicago | Illinois | 60612 | — |
| Midwestern Regional CTC /ID# 60744 | Zion | Illinois | 60099 | — |
| Johns Hopkins University /ID# 60759 | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital /ID# 64582 | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute /ID# 93833 | Boston | Massachusetts | 02215 | — |
| William Beaumont Hospital /ID# 95417 | Royal Oak | Michigan | 48073-6710 | — |
| Washington University-School of Medicine /ID# 62724 | St Louis | Missouri | 63110 | — |
| Beth Israel Medical Center /ID# 87993 | New York | New York | 10003 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 63222 | New York | New York | 10065-6007 | — |
| Duke University Medical Center /ID# 60747 | Durham | North Carolina | 27710-3000 | — |
| Penn State University and Milton S. Hershey Medical Center /ID# 62723 | Hershey | Pennsylvania | 17033 | — |
| University of Pennsylvania /ID# 60753 | Philadelphia | Pennsylvania | 19104-5502 | — |
| University of Pittsburgh MC /ID# 60758 | Pittsburgh | Pennsylvania | 15260 | — |
| University of Pittsburgh MC /ID# 65486 | Pittsburgh | Pennsylvania | 15260 | — |
| Medical University of South Carolina /ID# 60752 | Charleston | South Carolina | 29425 | — |
| The West Clinic /ID# 65487 | Memphis | Tennessee | 38120 | — |
| The West Clinic /ID# 94599 | Memphis | Tennessee | 38120 | — |
| The West Clinic /ID# 94600 | Memphis | Tennessee | 38120 | — |
| UT Southwestern Medical Center /ID# 60745 | Dallas | Texas | 75390-7208 | — |
| Houston Methodist Hospital - Scurlock Tower /ID# 60742 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01506609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01506609 live on ClinicalTrials.gov.